Abstract
BACKGROUND
Dengue virus (DENV) has circulated in Brazil for over 30 years. During this time, one serotype has cyclically replaced the other, until recently, when all four distinct serotypes began to circulate together. Persistent circulation of DENV for long time periods makes sequential infections throughout a person’s life possible. After primary DENV infection, life-long immunity is developed for the infecting serotype. Since DENV and Zika virus (ZIKV) are antigenically similar, the possibility of cross-reactions has attracted attention and has been demonstrated in vitro.
OBJECTIVE
The aim of this study was to investigate whether immune-sera from DENV and ZIKV infected patients would cross-react in vitro with other Flaviviridae family members.
METHODS
Cross-reaction of the studied samples with yellow fever virus (YFV), West Nile virus (WNV), Rocio virus (ROCV), Saint Louis virus (SLEV) and Ilheus virus (ILHV) has been investigated by plaque reduction neutralisation test (PRNT) and the antibody-dependent enhancement (ADE) by flow-cytometry.
FINDINGS
Antibodies against ZIKV and DENV virus cross-reacted with other flaviviruses either neutralising or enhancing the infection. Thus, viral entrance into FcRFcɣRII-expressing cells were influenced by the cross-reactive antibodies. ZIKV or DENV immune sera enhanced cellular infection by WNV, ILHV, ROCV and SLEV. Finally, DENV immune sera presented higher neutralising activity for YFV and SLEV. While ZIKV immune sera neutralised WNV, ILHV and ROCV with high frequencies of positivity.
MAIN CONCLUSIONS
The co-circulation of those viruses in the same area represents a risk for the development of severe infections if they spread throughout the country. Successive flavivirus infections may have an impact on disease pathogenesis, as well as on the development of safe vaccine strategies.
Keywords: ADE, flavivirus, dengue, Zika
Diseases caused by mosquito-borne flaviviruses, such as dengue virus (DENV), West Nile virus (WNV), yellow fever virus (YFV) and more recently Zika virus (ZIKV), are responsible for thousands of deaths and millions of hospitalisations worldwide each year. 1 In 2015, ZIKV, associated with congenital Zika syndrome, emerged in Brazil. The outbreak introduced a new “player” into the complex epidemiologic Brazilian scenario where other members of the Flaviviridae family, such as dengue 1-4, were already co-circulating. Therefore, one of the biggest ongoing concerns remains therefore, whether cross-reactivity due to previous flavivirus infection or vaccination can protect from or intensify disease in ZIKV-infected patients.
Sera from DENV exposed human and animals have been demonstrated to cross-react and enhance ZIKV infection in vitro; 2 , 3 , 4 , 5 nevertheless such cross-reactivity could neither be confirmed experimentally in vivo 6 nor in patients with acute ZIKV and a history of previous exposure to DENV. 7
The aim of this study was to investigate whether immune-sera from DENV and ZIKV infected patients would cross-react in vitro with other Flaviviridae family members such as YFV, WNV, Rocio virus (ROCV), Ilheus virus (ILHV) and Saint Louis virus (SLEV), assessing how such cross-reactivity hinders or enhances infection.
METHODS
Cell and viruses - BHK-21 and K562 (ATCC) cell lines were maintained respectively in minimum essential medium (MEM) and RPMI medium supplemented with 10% foetal bovine serum (FBS), 1% penicillin and 1% streptomycin and incubated at 37ºC with 5% CO2.
In the plaque reduction neutralisation test (PRNT) and antibody-dependent enhancement (ADE) assays the following strains were used: ZIKV PE243 strain, DENV-1, -2 and -4 (isolated from infected patients in the state of Pernambuco), 8 DENV-3 (derived from an infectious clone), 9 YFV 17D strain, YFV-prM/E-WNV, YFV-prM/E-ILHV, YFV-prM/E-SLEV and YFV-PrM/E-ROCV (viral chimeras built on a YFV 17D strain backbone where prM and E genes of YFV were exchanged for those of each flavivirus) (Gil et al., unpublished observation).
Human serum samples - A total of 19 sera were obtained from two cohort studies performed at the Universidade Federal da Paraíba (UFPB) (four samples) and at the Departamento de Virologia Instituto Aggeu Magalhães (IAM), Fundação Oswaldo Cruz (15 samples). Dengue and Zika fever cases were confirmed via virus isolation and/or viral RNA detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for dengue and ZIKV as previously described 10 - 11 and/or via positive serology for anti-DENV or anti-ZIKV IgM ELISA. 11 Seroconversion was determined by the presence of circulating specific IgG antibodies. Primary or secondary infections were determined according to the presence/absence of circulating anti-dengue IgG at the beginning of the ZIKV infection (Table I). Primary anti-DENV positive samples were collected before the 2015 ZIKV outbreak. Samples were named as follows: (i) DENV - samples were IgG positive for DENV and IgG negative for ZIKV; (ii) ZIKV - samples with active ZIKV infection and IgG negative for DENV; and (iii) ZIKV/DENV - samples with active ZIKV infection and IgG positive for DENV. Written informed consent was obtained from all subjects and the study was approved by the ethic committees of the UFPB (protocol #032/2009/CEP/HULW/UFPB) and IAM (CEP: 11/11).
TABLE I. Summary of dengue virus (DENV)- and Zica virus (ZIKV)-infected patients enrolled in the study.
| Patients ID | Age | Gender | ZIKV IgG | DENV IgG |
| P01 | 20 | F | POS | NEG |
| P05 | 20 | F | POS | NEG |
| P11 | 18 | F | POS | NEG |
| P13 | 15 | F | POS | NEG |
| P41 | 20 | F | POS | NEG |
| P03 | 28 | F | POS | POS (DV3,4) |
| P15 | 18 | F | POS | POS (DV3,4) |
| P67 | 28 | F | POS | POS (DV1,2,3,4) |
| P69 | 17 | F | POS | POS (DV3,4) |
| P71 | 20 | F | POS | POS (DV3,4) |
| P02 | 47 | F | NEG | POS (DV2) |
| P132 | 37 | M | NEG | NEG |
| P322 | 66 | F | NEG | POS (DV1) |
| P481 | 16 | M | NEG | POS (DV2) |
| P491 | 30 | M | NEG | POS (DV3) |
| P306 | 47 | F | NEG | POS (DV3) |
| P122 | 36 | F | NEG | POS (DV4) |
| P156 | 64 | M | NEG | POS (DV4) |
| P234 | 24 | F | NEG | POS (DV4) |
F: female; IgG: immunoglobulin G; M: male; NEG: negative; POS: positive.
Enhancement of virus infection in vitro assay - An ADE assay was performed with DENV and ZIKV immune sera collected from patients to test the augmentation of infection in FcɣRII-expressing K562 cell lines. Briefly, sera were serially diluted (1:10 to 1:10240), added to virus aliquots with 8 × 104 plaque forming units (PFU) for each studied virus and incubated for 20 minutes at room temperature. 1 × 105 K562 cells were added per well of a 96 well plates in order to obtain an multiplicity of infection (MOI) of 0.8 and were incubated for 1 hour at 37ºC. Cells were centrifuged for 5 minutes at 450 g and 25ºC, after which supernatants were aspirated, fresh medium was added to the wells and plates were incubated for 48 hours at 37ºC, 5% CO2. Cells were stained using a mouse monoclonal antibody anti flavivirus E protein (hybridoma D1-4G2-4-15, ATCC HB-112), prepared as tissue culture supernatant from hybridomas obtained from ATCC. The immune complex was detected with an anti-mouse Ab conjugated to FITC (Sigma, Saint Louis, MO, USA). Fluorescent cells were then quantified by flow cytometry and results were expressed as percentage of positive events. ADE assay was performed in duplicate and repeated once.
PRNT - PRNT 90 % (PRNT90) assays were performed in BHK-21 cells, as previously described. 12 Serial dilutions of previously positive DENV, ZIKV and DENV/ZIKV serum (1:10 to 1:5120) were mixed with 100 PFU of selected flaviviruses (ZIKV-PE243, YFV-17D, YFV-prM/E-WNV, YFV-prM/E-ILHV, YFV-prM/E-SLEV and YFV-PrM/E-ROCV), incubated for 1 hour at 37ºC, then added to the cells and incubated at 37ºC for an additional hour. After 1 hour of incubation, MEM containing 1.5 % carboxymethyl cellulose (CMC), 5% FBS and 1% penicillin-streptomycin were added to each well and plates were incubated at 37ºC, 5 % CO2 for 96 hours. After this incubation, plates were fixed with 10 % formaldehyde for 1 hour and subsequently stained with 1 % crystal violet for 15 minutes. Plaques were counted and the neutralisation capacity was estimated as the sera concentration causing a 90 % reduction in PFU. This assay was performed in duplicate and repeated once.
Statistical analysis - A nonparametric unpaired Mann-Whitney U test was used to compare the enhancing activity between tests and control. Results with p ≤ 0.05 were considered as statistically significant.
RESULTS
In vitro flavivirus neutralisation by convalescent-phase DENV, ZIKV and DENV/ZIKV immune sera - Four DENV samples (P322, P122, P156, P234) presented high cross neutralisation titres for ZIKV (1:320, 1:320, 1:5120, 1:5120, respectively) (Table II). Besides, DENV positive sera also neutralised YFV [P132 (1:151), P491(1:261), P306 (1:1006)], WNV [P491 (1:252)], ILHV [P132 (1:320), P234 (1:1280)], SLEV [P156 (1:1007), P234 (1:1280)]. On the other hand, ZIKV samples neutralised ILHV [P05, P15, P67, P71 (1:20 for each)], YFV [P05, P67 (1:20 for each)], WNV [P05 (1:138), P13 (1:20), P67 (1:49), P69 (1:20)], SLEV [P71 (1:20)], ROCV [P15, P67 (1:20 each)] (Table II).
TABLE II. Summary of plaque reduction neutralisation test (PRNT) titres and selected flavivirus infection enhancement by convalescent dengue virus (DENV)- and Zica virus (ZIKV)-infected samples.
| Sample ID | ZIKV | DENV1 | DENV2 | DENV3 | DENV4 | YFV | WNV | ILHV | SLEV | ROCV | |||||||
| ZIKV IgG+ | PRNT | PRNT | PRNT | PRNT | PRNT | PRNT | ADE | PRNT | ADE | PRNT | ADE | PRNT | ADE | PRNT | ADE | ||
| P01 | 2560 | <20 | <20 | <20 | <20 | <20 | 1.61 | <20 | 2.00 | <20 | 2.33 | <20 | 2.61 | <20 | 3.20 | ||
| P05 | 12980 | <20 | <20 | <20 | <20 | 20 | 1.12 | 138 | 1.33 | 20 | 1.81 | <20 | 2.26 | <20 | 1.47 | ||
| P11 | 634 | <20 | <20 | <20 | <20 | <20 | 1.19 | <20 | 1.60 | <20 | 1.59 | <20 | 1.50 | <20 | 1.69 | ||
| P13 | 1575 | <20 | <20 | <20 | <20 | <20 | 0.67 | 20 | 1.47 | <20 | 3.03 | <20 | 2.78 | <20 | 0.81 | ||
| P41 | 343 | <20 | <20 | <20 | <20 | <20 | 1.32 | <20 | 1.82 | <20 | 3.95 | <20 | 4.19 | <20 | 3.53 | ||
| P03 | 2560 | <20 | <20 | 320 | 80 | <20 | 1.21 | <20 | 2.36 | <20 | 2.90 | <20 | 3.64 | <20 | 4.65 | ||
| P15 | 1280 | <20 | <20 | 80 | 320 | <20 | 1.38 | <20 | 2.36 | 20 | 3.82 | <20 | 3.98 | 20 | 3.84 | ||
| P67 | 3729 | 63 | 67 | 340 | 2192 | 20 | 1.09 | 49 | 0.95 | 20 | 1.07 | <20 | 1.44 | 20 | 2.25 | ||
| P69 | 536 | <20 | <20 | 570 | 117 | <20 | 0.76 | 20 | 1.03 | <20 | 2.42 | <20 | 2.14 | <20 | 1.90 | ||
| P71 | 232 | <20 | <20 | 76 | 215 | <20 | 0.97 | <20 | 0.73 | 20 | 2.97 | 20 | 2.77 | <20 | 2.58 | ||
| ZIKV/DENV IgG- | P132 | <20 | 1.75 | <20 | <20 | <20 | <20 | 151 | 1.21 | 20 | 1.54 | 320 | 1.45 | <20 | 1.79 | <20 | 3.89 |
| DENV IgG+ | P02 | <20 | 3.31 | <20 | 5120 | <20 | <20 | <20 | 1.30 | <20 | 1.60 | <20 | 1.50 | <20 | 2.10 | <20 | 0.90 |
| P322 | 320 | 0.75 | 5120 | <20 | <20 | <20 | 20 | 1.32 | <20 | 2.84 | <20 | 0.91 | <20 | 1.08 | <20 | 2.02 | |
| P481 | <20 | 5.38 | 1280 | 5120 | 1280 | <20 | <20 | 1.73 | <20 | 1.90 | <20 | 5.21 | 20 | 4.82 | <20 | 4.06 | |
| P491 | <20 | 3.00 | 320 | 40 | >2560 | <20 | 261 | 1.30 | 252 | 2.57 | <20 | 2.03 | <20 | 2.38 | <20 | 2.59 | |
| P306 | <20 | 1.75 | 640 | 160 | >2560 | <20 | 1006 | 1.12 | <20 | 1.63 | <20 | 2.02 | <20 | 3.09 | <20 | 4.90 | |
| P122 | 320 | 1.00 | 280 | 5120 | 80 | 5120 | 20 | 1.20 | <20 | 1.17 | <20 | 1.21 | <20 | 1.80 | <20 | 1.71 | |
| P156 | 5120 | 0.38 | 320 | 320 | 80 | 1280 | <20 | 1.42 | <20 | 1.92 | <20 | 1.16 | 1007 | 1.28 | <20 | 0.06 | |
| P234 | 5120 | 0.38 | <20 | 1280 | 1280 | 5120 | <20 | 1.08 | <20 | 0.87 | 1280 | 0.73 | 1280 | 1.91 | <20 | 1.11 | |
ADE: antibody dependent enhancement; IgG: immunoglobulin G; ILHV: Ilheus virus; ROCV: Rocio virus; SLEV: Saint Louis encephalitis virus; WNV: West Nile virus; YFV: yellow fever virus.
DENV positive sera presented neutralising activity for YFV and SLEV than ZIKV samples, the frequencies of positivity for YFV and SLEV were 55.6 and 33.4 percent, respectively (Table III). While the ZIKV samples neutralised WNV, ILHV and ROCV with frequencies of positivity of 40, 40 and 20 %, respectively (Table III).
TABLE III. Frequency of positivity.
| PRNT90 (%) | |||||||||||
| ZIKV | DENV1 | DENV2 | DENV3 | DENV4 | YFV | WNV | ILHV | SLEV | ROCV | ||
| ZIKV IgG+ | Positives | 10 | 1 | 1 | 5 | 5 | 2 | 4 | 4 | 1 | 2 |
| (n) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
| (%) | 100 | 10 | 10 | 50 | 50 | 20 | 40 | 40 | 10 | 20 | |
| DENV IgG + | Positives | 4 | 6 | 7 | 6 | 3 | 5 | 2 | 2 | 3 | 0 |
| (n) | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | |
| (%) | 44.4 | 66.7 | 77.8 | 66.7 | 33.4 | 55.6 | 22.2 | 22.2 | 33.4 | 0 | |
DENV: dengue virus; IgG: immunoglobulin G; ILHV: Ilheus virus; PRNT: plaque reduction neutralisation test; ROCV: Rocio virus; SLEV: Saint Louis encephalitis virus; WNV: West Nile virus; YFV: yellow fever virus; ZIKV: Zika virus.
DENV or ZIKV immune sera deliver flavivirus virions to FcRFcɣRII-expressing cells - We tested the ability of DENV or ZIKV convalescent sera to promote ADE in the FcRFcɣRII-expressing cell line K562. ZIKV was preincubated with titrered convalescent anti-dengue serum and selected flaviviruses (ZIKV-PE243, YFV-17D, YFV-prM/E-WNV, YFV-prM/E-ILHV, YFV-prM/E-SLEV and YFV-prM/E-ROCV) were preincubated with convalescent DENV, ZIKV and ZIKV/DENV sera and then used to infect K562 cells. In all but three cases DENV sera increased ZIKV infection with a median 1.75-fold increase of infection by ZIKV-PE243 (Fig. A).
Flavivirus enhancement of infection by DENV- and ZIKV-immune sera. (A) enhancement of DENV-immune sera (n = 9) on ZIKV infection in K562 cells. horizontal bars indicate the median values; (B) six representative antibody dependent enhancement (ADE) curves (percentage of positive cells) of K562 cells infected with ZIKV-PE243; Infection enhancement of (C) YFV-prM/E-WNV; (D) YFV-17D; (E) YFV-prM/E-SLEV; (F) YFV-prM/E-ROCV; and (G) YFV-prM/E-ILHV chimeras by convalescent sera from positive DENV (n = 09), ZIKV (n = 5) and ZIKV/DENV patients (n = 5) donors was evaluated. Double comparisons with control group were performed by Mann Withney U test. *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001.
Six representative samples were serially diluted in order to assess whether the presence of neutralising antibodies against DENV samples would interfere with ZIKV entrance into K562 cells. Three samples at 1:10 dilution were shown to block (P122, P156 and P322) and three samples were shown to enhance (P02, P481 and P491) ZIKV entrance. With the increase of the dilution factor, neutralising samples became infection enhancers while the other samples reduced the number of positive cells (Fig. B). Thus, cross-reactive anti-DENV antibodies lead either to ADE or to neutralisation.
In general, DENV, ZIKV and ZIKV/DENV positive sera samples cross-reacted with WNV, YFV, SLEV, ROCV and ILHV, enhancing viral entrance in K562 cells (Fig. C-G). Specially, this held true for SLEV, ROCV and ILHV, which presented the highest levels of entrance (Fig. E-G). YFV infection was slightly increased in five samples (Fig. D), while WNV infection was increased in association with DENV and ZIKV samples (Fig. C).
DISCUSSION
Immunological cross-reactivity amongst members of the Flaviviridae family has been well described. Flaviviruses are immunologically and genetically related, with high levels of conservation of structural proteins E and prM, the main targets for adaptive immune responses. 13 , 14 ADE was initially described in secondary DENV infections, but may also occur among other flavivirus infections, influencing the disease pathogenesis, as well as the design of new vaccines against those flaviviruses.
Despite in vivo studies have demonstrated that previous DENV exposure does not result in more severe ZIKV infection, 6 , 7 we observed that controlled ZIKV infection of K562 cells was enhanced by DENV immune sera and our findings are in agreement with other previous reports. 2 , 3 The discrepancies between the different in vivo and in vitro assays might be owed to the rare occurrence of ADE, 15 once only few patients progress to severe dengue disease. In addition, the conditions outlined in in vitro experimentation are more limited with respect to cell interaction. Under in vivo conditions, a very large variety of cells can interact with the ZIKV and antibodies in the same environment and how this interaction may influence viral infectivity is still unclear. ADE should thus not be neglected and, despite the number of studies already available, it should be extensively explored, especially given the landscape of ongoing DENV vaccine trials.
Cross-reactivity is a hallmark of flavivirus infection due to antigenic similarity of these viruses, whether protection or infection enhancement will be displayed depends on the quantity and quality of pre-existing cross-reactive antibodies. 16 DENV serotypes present similarities in the envelope (E) protein at the amino acid sequence level; however they are antigenically different, due to amino acid differences that lead to structural changes in protein E viral protein. 17 In our results, we observed that sera from patients infected with DENV 1 and 4 serotypes neutralised ZIKV cell entrance, while sera from patients infected with DENV 2 and 3 serotypes enhanced ZIKV cell entrance. One possible reason for that could be the antigenic similarity/difference between DENV different serotypes and ZIKV. In fact, other study demonstrated that anti-DENV 3 immune sera cross-reacted more with ZIKV than another serotypes. 18
The neutralising ability of immune sera is directly influenced by the maturation stage of the viral particle, as observed in a previous study. 19 This phenomenon may have occurred in our study, both in the neutralisation studies of isolates and of the chimera and infectious clone. We can make this inference, since the infectious clones used in this study were previously characterised phenotypically and genetically, presenting similar replicative behaviour to the virus isolated.
In order to expand existing cross-reactivity studies, we tested the ability of sera from Dengue- and Zika-convalescent patients to recognise selected flaviviruses. Antibodies elicited against ZIKV enhanced or neutralised the flavivirus infections in different proportions. In this context, it is important to highlight that previous DENV infection did not interfere significantly with ZIKV enhancement.
YFV cellular entrance was slightly increased by ZIKV and DENV samples, especially by DENV patient’s sera. Therefore, circulating antibodies against DENV or ZIKV may not present an important threat for future YFV infection. This observation is especially important in places with known past or ongoing YFV outbreaks, as recently observed in Brazil. 20 Is important to state that the samples employed in this study were collected in Northeast Region of Brazil, where high levels of microcephaly cases associated with ZIKV recent outbreak were reported. In addition, most of the local population is not protected for YFV, since vaccination is not mandatory in this region. On the other hand, lack of YFV protection could be associated with congenital malformations observed in the last ZIKV outbreak in this region. Since, recent studies observed that vaccination against YFV led to the prevention of neurological problems in ZIKV infected mice. 21
Bardina et al. 2 demonstrated that the presence of anti-WNV antibodies increased levels of ZIKV infection in cell lines and in mice, the latter being evidenced by the increase of viral particles in animal tissues; they suggested that previous WNV infection would make ZIKV infection more severe. We however, demonstrate that the presence of anti-ZIKV antibodies increases WNV infection.
Cross-reaction may not be harmful to patients and certain samples also induced cross-protection with neutralisation titres ranging from 20 to 1,280 in a PRNT90. Neutralisation may lead to nonspecific infection control producing asymptomatic infections. As observed by Amarilla et al. 22 When reported that previous exposure to Ilheus and Saint Louis encephalitis viruses elicited cross-protection against ROCV infection in mice.
In the present study, we demonstrated that antibodies generated against ZIKV or DENV neutralised or enhanced the entrance of ROCV, SLEV, WNV and ILHV in K562 cells. Serological evidences showed those flaviviruses to be circulating in Brazil 22 , 23 and, considering that DENV and ROCV are endemic, the co-circulation of those viruses represents a risk for the development of severe infections if they spread throughout the country. Extensive in vivo studies should be undertaken to validate the actual potential of successive flavivirus infections for becoming increasingly severe as a result of cross-immunological reactions.
ACKNOWLEDGEMENTS
To Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco (Facepe) (grant BFP-0117-2.11/13), for granting RASO a visiting research fellowship and EFO-F (grant APQ 1380-5.05/15) and CNPq (DCR-0003-5.05/16), and to Louisa F. Ludwig-Begall, for the careful English proofreading of this manuscript.
Footnotes
RASO and EFO-F contributed equally to this work. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
REFERENCES
- 1.Mayer SV, Tesh RB, Vasilakis N. The emergence of arthropod-borne viral diseases a global prospective on dengue, chikungunya and zika fevers. Acta Trop. 2017;166:155–163. doi: 10.1016/j.actatropica.2016.11.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Sci. 2017;356(6334):175–180. doi: 10.1126/science.aal4365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Castanha PMS, Nascimento EJM, Braga C, Cordeiro MT, de Carvalho OV, de Mendonça LR. Dengue virus-specific antibodies enhance Brazilian Zika virus infection. J Infect Dis. 2017;215(5):781–785. doi: 10.1093/infdis/jiw638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol. 2016;17(9):1102–1108. doi: 10.1038/ni.3515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci United States Am. 2016;113(28):7852–7857. doi: 10.1073/pnas.1607931113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Pantoja P, Pérez-Guzmán EX, Rodríguez IV, White LJ, González O, Serrano C. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun. 2017;8:15674–15674. doi: 10.1038/ncomms15674. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Terzian ACB, Schanoski AS. Mota MT de O.da Silva RA.Estofolete CF.Colombo TE Viral load and cytokine response profile does not support antibody-dependent enhancement in dengue-primed Zika virus-infected patients. Clin Infect Dis. 2017;65(8):1260–1265. doi: 10.1093/cid/cix558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Cordeiro MT, Schatzmayr HG, Nogueira RMR, Oliveira de VF, Melo de WT, Carvalho de EF. Dengue and dengue hemorrhagic fever in the State of Pernambuco, 1995-2006. Rev da Soc Bras de Med Trop. 2007;40(6):605–611. doi: 10.1590/s0037-86822007000600001. [DOI] [PubMed] [Google Scholar]
- 9.Santos JJS, Cordeiro MT, Bertani GR, Marques ETA, Gil LHVG. A two-plasmid strategy for engineering a dengue virus type 3 infectious clone from primary Brazilian isolate. An Acad Bras Ciencias. 2014;86(4):1749–1759. doi: 10.1590/0001-3765201420130332. [DOI] [PubMed] [Google Scholar]
- 10.Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J Clin Microbiol. 1992;30(3):545–551. doi: 10.1128/jcm.30.3.545-551.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cordeiro MT, Brito CAA, Pena LJ, Castanha PMS, Gil LHVG, Lopes KGS. Results of a Zika virus (ZIKV) immunoglobulin M-specific diagnostic assay are highly correlated with detection of neutralizing anti-ZIKV antibodies in neonates with congenital disease. J Infect Dis. 2016;214(12):1897–1904. doi: 10.1093/infdis/jiw477. [DOI] [PubMed] [Google Scholar]
- 12.Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21(2):123–132. doi: 10.1089/vim.2008.0007. [DOI] [PubMed] [Google Scholar]
- 13.Priyamvada L, Hudson W, Ahmed R, Wrammert J. Humoral cross-reactivity between Zika and dengue viruses implications for protection and pathology. Emerg Microbes & Infect. 2017;6(5):e33. doi: 10.1038/emi.2017.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Reynolds CJ, Suleyman OM, Ortega-Prieto AM, Skelton JK, Bonnesoeur P, Blohm A. T cell immunity to Zika virus targets immunodominant epitopes that show cross-reactivity with other flaviviruses. Sci Reports. 2018;8(1):672–672. doi: 10.1038/s41598-017-18781-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.George J, Valiant WG, Mattapallil MJ, Walker M, Huang Y-JS , Vanlandingham DL. Prior exposure to Zika virus significantly enhances peak dengue-2 viremia in Rhesus macaques. Sci Reports. 2017;7(1):10498–10498. doi: 10.1038/s41598-017-10901-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci United States Am. 2016;113(3):728–733. doi: 10.1073/pnas.1522136113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Katzelnick LC, Fonville JM, Gromowski GD, Bustos Arriaga J, Green A, James SL. Dengue viruses cluster antigenically but not as discrete serotypes. Sci. 2015;349(6254):1338–1343. doi: 10.1126/science.aac5017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, Cárdenas M, Katzelnick LC. Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. Nat Commun. 2019;10(1):938–938. doi: 10.1038/s41467-019-08845-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol. 2014;88(20):11726–11737. doi: 10.1128/JVI.01140-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Goldani LZ. Yellow fever outbreak in Brazil, 2017. Braz J Infect Dis. 2017;21(2):123–124. doi: 10.1016/j.bjid.2017.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kum DB, Mishra N, Boudewijns R, Gladwyn-Ng I, Alfano C, Ma J. A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. NPJ VCaccines. 2018;3:56–56. doi: 10.1038/s41541-018-0092-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Amarilla AA, Fumagalli MJ, Figueiredo ML, Lima-Junior DS, Santos-Junior NN, Alfonso HL. Ilheus and Saint Louis encephalitis viruses elicit cross-protection against a lethal Rocio virus challenge in mice. PloS One. 2018;13(6):e0199071. doi: 10.1371/journal.pone.0199071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.de Oliveira-Filho EF, Oliveira RAS, Ferreira DRA, Laroque PO, Pena LJ, Valença-Montenegro MM. Seroprevalence of selected flaviviruses in free-living and captive capuchin monkeys in the state of Pernambuco, Brazil. Transbound Emerg Dis. 2018;65(4):1094–1097. doi: 10.1111/tbed.12829. [DOI] [PubMed] [Google Scholar]